Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Helge Bischoff"'
Autor:
Miriam Blasi, Martin E. Eichhorn, Petros Christopoulos, Hauke Winter, Claus Peter Heußel, Felix J. Herth, Rami El Shafie, Katharina Kriegsmann, Mark Kriegsmann, Albrecht Stenzinger, Helge Bischoff, Michael Thomas, Jonas Kuon
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ 75 years. In this study we evaluated efficacy a
Externí odkaz:
https://doaj.org/article/1b53ff915d164d97a52c735bb73255f9
Autor:
David Fisch, Farastuk Bozorgmehr, Daniel Kazdal, Jonas Kuon, Laura V. Klotz, Rajiv Shah, Florian Eichhorn, Mark Kriegsmann, Marc A. Schneider, Thomas Muley, Albrecht Stenzinger, Helge Bischoff, Petros Christopoulos
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundLarge-cell neuroendocrine lung carcinoma (LCNEC) is a rare pulmonary neoplasm with poor prognosis and limited therapeutic options.MethodsWe retrospectively analyzed all patients with metastatic LCNEC in the records of a large German academi
Externí odkaz:
https://doaj.org/article/e1f6b634e2764da99e782889394b3710
Autor:
Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann, Martin E. Eichhorn
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatmen
Externí odkaz:
https://doaj.org/article/50b5756cf3ef479797e0cc786108831c
Autor:
Alexandros Papachristofilou, Madeleine M. Hipp, Ute Klinkhardt, Martin Früh, Martin Sebastian, Christian Weiss, Miklos Pless, Richard Cathomas, Wolfgang Hilbe, Georg Pall, Thomas Wehler, Jürgen Alt, Helge Bischoff, Michael Geißler, Frank Griesinger, Karl-Josef Kallen, Mariola Fotin-Mleczek, Andreas Schröder, Birgit Scheel, Anke Muth, Tobias Seibel, Claudia Stosnach, Fatma Doener, Henoch S. Hong, Sven D. Koch, Ulrike Gnad-Vogt, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine
Externí odkaz:
https://doaj.org/article/99e04455f1444be88b66a788433ed6e0
Autor:
Nikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, Daniel Kazdal, Martina Kirchner, Felix J. Herth, Claus-Peter Heussel, Florian Eichhorn, Michael Meister, Thomas Muley, Rami A. Elshafie, Jürgen R. Fischer, Martin Faehling, Mark Kriegsmann, Peter Schirmacher, Helge Bischoff, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Epidermal growth factor receptor-mutated (EGFR + ) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging. Methods: EGFR + NSCL
Externí odkaz:
https://doaj.org/article/cc0d2140121c4e9798dd4c51c532b090
Autor:
Jonathan W. Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H. Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lu, Alvaro Taus, Manuel Cobo, Shawn T. Estrem, Sameera R. Wijayawardana, Kellie Turner, Gerard Joseph Oakley, Karla C. Hurt, Alan Y. Chiang, Anwar M. Hossain, William J. John, Luis Paz-Ares
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
IntroductionJUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell lung cancer (NSCLC) harboring a Kirsten rat sarcoma (KRAS) mutation.MethodsJUNI
Externí odkaz:
https://doaj.org/article/4c938db73a4443b18e2317f0a0f304fd
Autor:
G. Speranza, Helge Bischoff, Enriqueta Felip, Steven Francis Powell, Shirish M. Gadgeel, Maximilian Hochmair, F. De Angelis, Manuel Domine, Emilio Esteban, Edward B. Garon, Delvys Rodriguez-Abreu, Takayasu Kurata, J. Yang, N. Peled, Rina Hui, Martin Reck, S. Cheng, M.C. Pietanza, Fabricio Souza, M.C. Garassino, Michael Boyer
Publikováno v:
Annals of Oncology. 32:881-895
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9f0ee1ef0ca1964e2c7c0781703bea
https://doi.org/10.1016/j.annonc.2021.04.008
https://doi.org/10.1016/j.annonc.2021.04.008
Autor:
Marina C. Garassino, Julien Mazieres, Martin Reck, Christos Chouaid, Helge Bischoff, Niels Reinmuth, Laura Cove-Smith, Talal Mansy, Diego Cortinovis, Maria R. Migliorino, Angelo Delmonte, José Garcia Sánchez, Luis Enrique Chara Velarde, Reyes Bernabe, Luis Paz-Ares, Ignacio Diaz Perez, Nataliya Trunova, Kayhan Foroutanpour, Corinne Faivre-Finn
On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efc6fad6c65ed3b06a5139f97da1aa1d
https://hdl.handle.net/10668/22343
https://hdl.handle.net/10668/22343
Autor:
Christiane Wiedemann, Daniel Kazdal, Jelena Cvetkovic, Julia Kunz, David Fisch, Martina Kirchner, Mark Kriegsmann, Holger Sueltmann, Claus-Peter Heussel, Helge Bischoff, Michael Thomas, Albrecht Stenzinger, Petros Christopoulos
Publikováno v:
Cold Spring Harbor molecular case studies. 8(6)
Large-cell neuroendocrine lung carcinoma (LCNEC) is a high-grade neoplasm with median survival of 1 year and limited therapeutic options. Here, we report the unusual case of a 47-year-old female smoker with stage IV LCNEC featuring EML4-ALK variant 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36cc7c08fa38680392d441d9c3886b06
https://pubmed.ncbi.nlm.nih.gov/36207130
https://pubmed.ncbi.nlm.nih.gov/36207130
Autor:
Rajkumar Savai, Florian Eichhorn, Inka Zoernig, Michael Thomas, Thomas Muley, Martin E. Eichhorn, Laura V. Klotz, Hauke Winter, Dirk Jaeger, Marc A. Schneider, Katharina Kriegsmann, Mark Kriegsmann, Helge Bischoff, Claus Peter Heussel, Hans Hoffmann, Uwe Haberkorn
Publikováno v:
Lung Cancer. 153:150-157
Objectives A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery for the treatment of non-small cell lung cancer (NSCLC) has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f9ecf24000bb91c608cf220a42e3d60
https://doi.org/10.1016/j.lungcan.2021.01.018
https://doi.org/10.1016/j.lungcan.2021.01.018